Bacillus anthracis spores are an appealing biological weapon, which can be distributed through many different means to cause bioterrorism, such as the intentional contamination of the U.S. mail after the September 11 terrorist attacks. Anthrax vaccine adsorbed (AVA), the only human anthrax vaccine in the U.S., was licensed for the prevention of cutaneous anthrax and requires initial multiple injections with subsequent annual boosters. Thus, there is a critical need to develop an efficacious and easily administrable vaccine to protect against anthrax infection, especially the inhalation anthrax, the most lethal form of anthrax. New anthrax vaccine development has been focused on the production of a vaccine based on purified protective antigen (PA) protein of the anthrax toxin. However, it was shown that, besides the PA, other antigens such as the lethal factor (LF), a protein that binds to PA to form anthrax lethal toxin, and the poly-gamma-D-glutamic acid (PGA) capsule surrounding the vegetative anthrax bacilli, should also be included in an anthrax vaccine for more effective protection. A nasal multi- antigen anthrax vaccine will be advantageous not only because it will be ease to administer, but also because it is expected to induce immune responses against all antigens in both the systemic compartment and the mucosal tissues of the respiratory tract, through which inhaled anthrax spores enter hosts. Data from recent studies have indicated the importance of the anti-PA mucosal responses in preventing against inhalational anthrax challenges in animals. We propose to develop an efficacious nasal anthrax vaccine that can induce specific systemic and mucosal immune responses against both the anthrax toxins and the vegetative bacilli by incorporating a 63 kDa form of PA, an inactivated LF mutant, and PGA as antigens into a lipid-based particulate vaccine carrier we have developed. We hypothesize that that this tri-antigen nasal vaccine will be more effective in preventing against an inhalational anthrax infection than the systemic injection of a vaccine based on PA alone.
Our specific aims are to define the immune responses induced by this tri-antigen nasal anthrax vaccine in mice (aim 1), to evaluate the anti-toxin and anti-bacillus activities induced by it (aim 2), and to validate the efficacy of this vaccine in preventing against a pulmonary anthrax spore challenge in mice (aim 3). The completion of this project is expected provide a sound scientific foundation for further developing this vaccine into an efficacious and easily administrable nasal anthrax vaccine for humans. The development of a prototype nasally administrable multi-antigen anthrax vaccine that targets both anthrax toxins and bacilli and the validation of its efficacy in a murine model will provide a sound foundation for the development of a new generation human anthrax vaccine, which is urgently needed for effective mass immunization in case of a covert anthrax outbreak. The same vaccine or its modified version can also be used in agricultural industries to vaccinate cattle. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AI070538-01A1
Application #
7258190
Study Section
Vaccines Against Microbial Diseases (VMD)
Program Officer
Zou, Lanling
Project Start
2007-09-20
Project End
2009-08-31
Budget Start
2007-09-20
Budget End
2008-08-31
Support Year
1
Fiscal Year
2007
Total Cost
$173,510
Indirect Cost
Name
Oregon State University
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
053599908
City
Corvallis
State
OR
Country
United States
Zip Code
97339
Li, Xinran; Aldayel, Abdulaziz M; Cui, Zhengrong (2014) Aluminum hydroxide nanoparticles show a stronger vaccine adjuvant activity than traditional aluminum hydroxide microparticles. J Control Release 173:148-57
Kumar, Amit; Li, Xinran; Sandoval, Michael A et al. (2011) Permeation of antigen protein-conjugated nanoparticles and live bacteria through microneedle-treated mouse skin. Int J Nanomedicine 6:1253-64
Li, Xinran; Sloat, Brian R; Yanasarn, Nijaporn et al. (2011) Relationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental design. Eur J Pharm Biopharm 78:107-16
Yanasarn, Nijaporn; Sloat, Brian R; Cui, Zhengrong (2011) Negatively charged liposomes show potent adjuvant activity when simply admixed with protein antigens. Mol Pharm 8:1174-85
Sloat, Brian R; Sandoval, Michael A; Cui, Zhengrong (2010) Towards preserving the immunogenicity of protein antigens carried by nanoparticles while avoiding the cold chain. Int J Pharm 393:197-202
Oyewumi, Moses O; Kumar, Amit; Cui, Zhengrong (2010) Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines 9:1095-107
Sloat, Brian R; Sandoval, Michael A; Hau, Andrew M et al. (2010) Strong antibody responses induced by protein antigens conjugated onto the surface of lecithin-based nanoparticles. J Control Release 141:93-100
Sloat, Brian R; Shaker, Dalia S; Le, Uyen M et al. (2008) Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens. FEMS Immunol Med Microbiol 52:169-79